MethylGene Inc.

MethylGene Inc.

September 08, 2009 07:30 ET

MethylGene to Present Data at the 49th Annual ICAAC Meeting

Reporting Phase I Clinical Data for Antifungal Agent, MGCD290, and Preclinical Data for Clinical Candidate, MG96077, a Broad-Spectrum Beta-Lactamase Inhibitor for Bacterial Infections

MONTREAL, QUEBEC--(Marketwire - Sept. 8, 2009) - September 8, 2009 - MethylGene Inc. (TSX:MYG) today announced that Phase I clinical data for its Hos2 fungal inhibitor, MGCD290, will be reported at an oral presentation and poster session; and preclinical data for its clinical candidate, MG96077, a broad-spectrum, beta-lactamase inhibitor for bacterial infections, will be reported in a poster presentation at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Meeting which will be held from September 12th to 15th, 2009 in San Francisco, California.

The following are the session details:

Oral Presentation

MGCD290: A Novel Small Molecule, Modulates Azole Antifungal Activity through
Specific Inhibition of the Histone Deacetylase Hos2

Presentation No.: M-1919

Presenter: Dr. Jeffrey M. Besterman, Chief Scientific Officer, MethylGene Inc.

Location: Room 104

Time: Tuesday, September 15, 8:30 a.m. to 8:45 a.m. PDT

Poster Presentations

Multiple Phase I Studies in Healthy Subjects Demonstrate Safety and
Pharmacokinetics of MGCD290, an Oral Fungal Hos2 Inhibitor +/- Fluconazole

Presentation No.: M-1029

Poster No.: 519

Location: Hall B

Time: Sunday, September 13, 10:00 a.m. to 4:30 p.m. PDT

Novel Beta-Lactamase Inhibitor Potentiates and Extends the Antibacterial

Activity of Imipenem against Beta-Lactam-Resistant P. aeruginosa and K. pneumoniae

Presentation No.: C1-1373

Poster No.: 114

Location: Hall B

Time: Monday, September 14, 10:00 a.m. to 4:30 p.m. PDT

About MethylGene

MethylGene Inc. (TSX:MYG) is a publicly-traded, clinical stage, biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics with a focus on cancer. The Company's product candidates include: MGCD265, an oral, multi-targeted kinase inhibitor targeting the c-Met, VEGF, Ron and Tie-2 receptor tyrosine kinases that is in Phase II clinical trials for cancers; MGCD290, a fungal Hos2 (HDAC) inhibitor being developed for use in combination with fluconazole for serious fungal infections that is in Phase I clinical studies; and MGCD0103, an oral, isoform-selective HDAC inhibitor which has been in multiple clinical trials for solid tumors and hematological malignancies and is licensed to Taiho Pharmaceutical Co. Ltd. A fourth compound discovered using MethylGene's HDAC platform, EVP-0334 - a potential cognition enhancing agent, is in a Phase I study sponsored by EnVivo Pharmaceuticals Inc. MethylGene also has a funded collaboration with Otsuka Pharmaceutical Co. Ltd. for applications in ocular diseases using the Company's proprietary kinase inhibitor chemistry. Please visit our website at

Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Such statements, based as they are on the current expectations of management of MethylGene, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond MethylGene's control. These risks and uncertainties could cause future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Such results, performance or achievements include, but are not limited to, the timing and effects of regulatory action; the continuation of collaborations; the results of clinical trials; the timing of enrollment or completion of clinical trials; the success, efficacy or safety of MGCD0103, MGCD265 or MGCD290; the ability to scale up, formulate and manufacture sufficient GMP, clinical or commercialization quantities of MGCD0103, MGCD265 or MGCD290, and the relative success or the lack of success in developing and gaining regulatory approval and/or market acceptance for any compound or new product including MGCD0103, MGCD265 or MGCD290. Such risks include, but are not limited to, the impact of general economic conditions, economic conditions in the pharmaceutical industry, changes in the regulatory environment in the jurisdictions in which MethylGene does business, stock market volatility, fluctuations in costs, expectations with respect to our intellectual property position and our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others, changes in the competitive landscape including changes in the standard of care for the various indications in which MethylGene is involved, and changes to the competitive environment due to consolidation, as well as other risks, which you are urged to read, as described in MethylGene's Annual Information Form for the fiscal year ending December 31, 2008, under the heading 'risk factors and all other documents filed by the Company that can be found at Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. The reader should not place undue reliance on the forward-looking statements included in this presentation. These statements speak only as an update on the date they are made and MethylGene is under no obligation to revise such statements as a result of any event, circumstance or otherwise except in accordance with law.

Contact Information